Aromatase inhib 
Welcome,         Profile    Billing    Logout  
 6 Companies  6 Products   6 Products   149 Diseases   443 Trials   11350 News 


«12...4567891011121314...7576»
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Journal, Metastases:  Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2- Metastatic Breast Cancer. (Pubmed Central) -  Sep 28, 2023   
    Likewise, indirect treatment comparison between ribociclib vs. palbociclib (one-stage: HR = 0.903, 95%-CI: 0.746-1.094, p = 0.297), abemaciclib vs. palbociclib (one-stage: HR = 0.843, 95%-CI: 0.690-1.030, p = 0.094) and abemaciclib vs. ribociclib (one-stage: HR = 0.933, 95%-CI: 0.753-1.157, p = 0.528) failed to demonstrate a significant OS difference. Findings from this indirect treatment comparison suggest no significant PFS or OS differences between CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- MBC.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
    Review, Journal:  Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review. (Pubmed Central) -  Sep 25, 2023   
    Randomized phase 3 studies demonstrated that the addition of CDK4/6i reduced the hazard risk of disease progression by approximately half compared with hormonal monotherapy (an aromatase inhibitor, tamoxifen, or fulvestrant) in the first-line (1L) and/or second-line (2L) setting...Finally, given the lack of endocrine responsiveness following progression on some CDK4/6i, strategies to optimally sequence treatment are needed. Future research should focus on defining the role of each CDK4/6i in HR+ breast cancer and developing a biomarker-directed integration of these agents.
  • ||||||||||  tamoxifen / Generic mfg.
    Journal:  Geospatial availability of breast cancer treatment modalities and hypothetical access improvement in Ghana: A nationwide survey. (Pubmed Central) -  Sep 19, 2023   
    Level 3 included Tamoxifen and surgery (mastectomy with axillary lymph node sampling); Level 2 included Level 3 plus radiation, aromatase inhibitors, lumpectomy, and sentinel lymph node biopsy; Level 1 included Level 2 plus Her2 therapy and breast reconstruction...Multi-modal breast cancer treatment is available in Ghana, but it is not accessible to most of the population. Leveraging the knowledge of current resources and population proximity provides an opportunity to identify high-yield areas for targeted expansion.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Retrospective data, Journal:  Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry. (Pubmed Central) -  Sep 18, 2023   
    The potential beneficial or detrimental effects of the different drugs evaluated on fracture risk are masked by treatment with anabolic or antiresorptive drugs that have a more potent action on bone metabolism, with two exceptions: letrozole and oral corticosteroids. These findings may have important clinical implications, as patients receiving these treatments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs such as denosumab or teriparatide.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal, Real-world evidence, Real-world:  Determinants of response to CDK4/6 inhibitors in the real-world setting. (Pubmed Central) -  Sep 13, 2023   
    P=N/A
    Together, these data suggest that there are distinct pathological and biological features of HR+/HER2- breast cancer associated with response to CDK4/6 inhibitors. Clinical trial registration number: NCT04526587.
  • ||||||||||  tamoxifen / Generic mfg., fulvestrant / Generic mfg.
    Review, Journal:  Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? (Pubmed Central) -  Sep 8, 2023   
    The new oral selective estrogen receptor degraders, which are capable of reducing ER protein expression and blocking estrogen-dependent and -independent ER signaling, have a broader spectrum of activity against ESR1 mutations and seem to be a promising means of overcoming the failure of standard ET. The aim of this review is to summarize the development of oral selective estrogen receptor degraders, their current status, and their future perspectives.
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Journal:  ESR1 Mutation-Positive Recurrent Breast Cancer Successfully Treated with Letrozole plus Abemaciclib (Pubmed Central) -  Aug 27, 2023   
    One of the resistance mechanisms is mutations in the ESR1 gene, which have also been found to occur after long-term aromatase inhibitor(AI)treatment. Here, we describe our experience of a case in which long-term PR was achieved with AI(letrozole)plus abemaciclib despite ESR1 mutation positivity in cancer genetic screening and review the literature.
  • ||||||||||  tamoxifen / Generic mfg.
    Review, Journal:  Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and Perspectives. (Pubmed Central) -  Aug 26, 2023   
    This must be balanced against the long-term side effects of endocrine treatment and the competing risks. For patients with an intermediate risk, 7 years appears to be the optimal duration, and in those with high-risk features, endocrine therapy up to 10 years may be considered.
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg., fulvestrant / Generic mfg.
    Review, Journal:  Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options. (Pubmed Central) -  Aug 26, 2023   
    Furthermore, HT has recently been combined with targeted therapies, but most studies evaluating these combinations are still ongoing. The main aim of this review is to provide an overview of the progress made in the last decade to characterize the biological and prognostic role of HRs for EOC and the developments in their therapeutic targeting through HT.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Experience of the Implementation of a Payment for Performance Based on a Risk Sharing Agreement Scheme in Argentina: Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients () -  Aug 25, 2023 - Abstract #ISPOREU2023ISPOR_EU_136;    
    The 46 patients who received ribociclib in combination with a non steroidal aromatase inhibitor or fulvestrant during the first year of PBRSA implementation were included in the analysis. At month 12, 6 out of the 46 patients were regarded as treatment failures (3 disease progression, 2 deaths and 1 withdrawals due to toxicity), Direct costs of ribociclib using a traditional payment scheme plus an PBRSA compared to the traditional purchase-only scenario were 7.94% lower.Lessons Learned: This work demonstrated that it is feasible to implement an PBRSA in Argentina, being essential for its realization a strategic association between the stakeholders involved.Stakeholder perspective: For the implementation of the PBRSA we taken into account the perspective of the different Stakeholders: prepaid medical plans, Pharmaceutical Company, Pharmaceutical Benefit Management and audit team.
  • ||||||||||  tamoxifen / Generic mfg.
    Journal:  Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer. (Pubmed Central) -  Aug 21, 2023   
    The findings of this study will contribute to implementing individual cancer care based on the characteristics and needs of patient subgroups, which may improve the allocation of medical resources and provide interventions tailored to patients' unique needs. The decision regarding adjuvant therapy should be made considering clinical and genomic risks and age, and clinicians should consult with patients about adverse effects and compliance.
  • ||||||||||  Journal:  Novel oxadiazole-thiadiazole derivatives: synthesis, biological evaluation, and in (Pubmed Central) -  Aug 17, 2023   
    Denosumab is effective to induce early increase of TBS and reduction in risk of VFs. In vitro and in silico studies suggest two important structure-activity relationship (SAR) points that at least one azole ring is essential, and if there is approximately 8.0?
  • ||||||||||  Review, Journal:  Targeting nuclear hormone receptors for the prevention of breast cancer. (Pubmed Central) -  Aug 16, 2023   
    Among these include drugs that target other nuclear receptors, such as retinoic acid receptor (RAR), retinoid X receptor (RXR) and vitamin D receptor (VDR). In this review we provide an overview of recent preclinical and clinical trials targeting members of the nuclear receptor superfamily for the prevention of breast cancer.
  • ||||||||||  Review, Journal:  Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Current Perspectives on the Role of Laser Therapy. (Pubmed Central) -  Aug 14, 2023   
    Although evidence for laser efficacy in BCSs comes mostly from single-arm prospective studies, with only one randomized double-blind sham-controlled trial for CO laser and one randomized comparative trial of erbium laser and hyaluronic acid, available data are reassuring in the short term and indicate effectiveness of both CO and erbium lasers on the most common GSM symptoms. However, further studies are mandatory to establish long-term efficacy and safety in menopausal women, including BCSs.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents. (Pubmed Central) -  Aug 11, 2023   
    Molecular docking and molecular dynamics calculations on the interaction of 6 or letrozole with the aromatase binding site revealed that the ferrocene moiety increases the van der Waals and hydrophobic interactions, thus resulting in an increase in binding affinity. Furthermore, the iron atom of the ferrocene fragment can form a metal-acceptor interaction with a propionate fragment, and this results in a stronger coupling with the heme group-a possibility that is consistent with the strong aromatase inhibition of 6.